Decreased but persistent epigenetic age acceleration is associated with changes in T-cell subsets after initiation of highly active antiretroviral therapy in persons living with HIV

By sjmartinez • June 10, 2024

Sehl ME, Breen EC, Shih R, Li F, Zhang J, Langfelder P, Horvath S, Bream JH, Duggal P, Martinson J, Wolinsky SM, Martinez-Maza O, Ramirez CM, Jamieson BD. Decreased but persistent epigenetic age acceleration is associated with changes in T-cell subsets after initiation of highly active antiretroviral therapy in persons living with HIV. Front Bioinform. 2024 May 24;4:1356509. doi: 10.3389/fbinf.2024.1356509. PMID: 38855141; PMCID: PMC11157435.

Tags: Aging, antiretroviral therapy, DNA methylation, Epigenetic clock, Hematology/Oncology, human immunodeficiency virus, Publications

Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report

Fitzsimmons KC, Fajardo MA, Noor Z. Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a[...]

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

Hecht JR, Michot JM, Bajor D, Patnaik A, Chung KY, Wang J, Falchook G, Cleary JM, Kim R, Krishnamurthy A, Marathe O, Youssoufian H, Ellis[...]

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu[...]